Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 10/20 | 0.45 |
| ▸ | RPS6KA2 | Q15349 | 4/20 | 0.36 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 6/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4829943 | 0.90 | SMN1; SMN2 (0.37) | RPS6KA3RPS6KA2SLC40A1MAPKAPK2MAPK8 | |
| SCHEMBL4828067 | 0.82 | RPS6KA3 (0.45) | RPS6KA3RPS6KA2SLC40A1MAPKAPK2FGFR1 | |
| SCHEMBL271134 | 0.81 | RPS6KA3 (0.46) | RPS6KA3RPS6KA2FGFR1 | |
| SCHEMBL16354331 | 0.72 | ACLY (0.36) | RPS6KA3FGFR1JAK2JAK1TYK2 | |
| SCHEMBL4823794 | 0.72 | SMN1; SMN2 (0.37) | RPS6KA3RPS6KA2SLC40A1MAPKAPK2FGFR1 | |
| SCHEMBL4829827 | 0.72 | RPS6KA3 (0.41) | RPS6KA3RPS6KA2SLC40A1MAPKAPK2FGFR1 | |
| SCHEMBL4830051 | 0.71 | SMN1; SMN2 (0.37) | RPS6KA3RPS6KA2SLC40A1MAPKAPK2MAPK8 | |
| SCHEMBL270972 | 0.71 | POLB (0.40) | RPS6KA3RPS6KA2FGFR1 | |
| SCHEMBL4829961 | 0.68 | SMN1; SMN2 (0.40) | RPS6KA3RPS6KA2SLC40A1MAPKAPK2FGFR1 | |
| SCHEMBL4823385 | 0.67 | RPS6KA3 (0.41) | RPS6KA3RPS6KA2SLC40A1MAPKAPK2MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348425-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| WO-2007092000-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| US-7153848-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060166964-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
| US-20060046983-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166964-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | RPS6KA3 684/4885RPS6KA2 984/4885SLC40A1 2619/4885 |
| US-20060046983-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | RPS6KA3 684/4885RPS6KA2 984/4885SLC40A1 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.